Skip to main content

Table 3 Choice of antiretroviral regimen

From: UK national clinical audit: management of pregnancies in women with HIV

CD4 count (cells/mm3)

Viral load (copies/mL)

BHIVA recommendationa

Number of women

In accordance with recommendation

≤350

-

TVD/FTC, ABC/3TC or ZDV/3TC + EFV, NVP or bPI

214

93%

>350

>100,000

TFV/FTC, ABC/3TC or ZDV/3TC + bPI

11

100%

10,000 – 100,000

As above or ZDV/3TC/ABC

81

99%

<10,000

As above or ZDV monotherapy

162

98%

unknown

-

84

-

  1. TVD truvada, FTC emtricitabine, ABC abacavir, 3TC lamivudine, ZDV zidovudine, EFV efavirenz, NVP nevirapine, bPI boosted protease inhibitor
  2. aRaltegravir was accepted as an alternative to EFV/NVP/bPI when started after the first trimester